Table 10.
Comparative infection adverse event data for TPE in MG.
| Reference | Lal et al. (54) | Köhler et al. (53) | Barth et al. (5) | Pittayanon et al. (50) | Qureshi et al. (42) | Köhler et al. (52) | Schneider-Gold et al. (51) | Liew et al. (25) | Rønager et al. (45) | Sarkar et al. (55) | Saeteng et al. (56) | El-Bawab et al. (64) | Mandawat et al. (1) | Guptill et al. (62) | Mandawat et al. (63) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment context | Acute | Acute | Acute | Acute | Acute | Acute | Acute | Chronic | Chronic | Peri-op | Peri-op | Peri-op | Mixed | Mixed | Mixed |
| Comparison | TPE/No TPE*** | TPE/No TPE*** | TPE/IVIG | TPE/IVIG | TPE/IVIG | TPE/lA | TPE/lA | TPE/IVIG | TPE/IVIG | TPE/No TPE | TPE/No TPE | TPE all pts/TPEselective | TPE/IVIG | TPE peripheral/ TPE central** |
TPE early/TPE delayed |
| Timing | hosp. | hosp. | 30 d | hosp. | hosp. | 180 d | hosp. | 1 yr* | 16 wk | hosp. | hosp. | hosp. | hosp. | Tx | hosp. |
| # Patients | 4/3 | 21/42 | 41/40 | 21/9 | 28/26 | 10/9 | 19/24 | 17/20 | 12/12 | 10/9 | 33/53 | 74/90 | 1,269/340 | 100/34 | 870/183 |
| Infection (unspecified/ other) |
- | - | - | - | 21/8% | 0/11% | - | - | - | 20/56% | 0/2% | 3/1% | 5/1%∧ | - | 3/8%∧ |
| Pneumonia | 75/33% | 24/14% | 0/3% | 19/11% | - | 10/22% | 5/8% | - | - | 10/33% | - | - | - | - | - |
| Bacteremia | 25/0% | - | - | - | - | - | - | - | - | - | - | - | - | 1/3% | - |
| Sepsis | 0/33% | 5/0% | - | - | - | 20/0% | - | 6/0% | 8/0% | - | - | - | - | 1/3% | - |
hosp, during hospitalization; Tx, during treatment period; lA, immunoadsorption.
No significant difference observed between treatments (p ≥ 0.05) unless noted.
∧
p < 0.05 as reported by original authors or calculated using Fisher exact test.
*
Timing: (44) through hospitalization or later, (25) median 1 yr follow-up (range 0-5 yrs), (10) mean 116 mo for all patients (100.2 ± 41.2 mo TPE vs. 125.1 ± 77.5 mo No TPE).
**
peripheral venous access and central venous access.